Clinical trials · New York
Ulcerative Colitis clinical trials in New York
We’re tracking 36 recruiting ulcerative colitis studies with a site in New York — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07845487RecruitingPhase 2
Study of PALI-2108 for moderate to severe ulcerative colitis
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Albany, New YorkAges 18–75 - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
New York, New YorkAges 18 years+ - NCT07470879RecruitingPhase 2
Etrasimod for Children with Ulcerative Colitis
This trial tests if the medicine etrasimod can help children with moderate to severe ulcerative colitis. You may still be able to join even if you are already taking other treatments for your condition.
New York, New YorkAges 2–11 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Stony Brook, New YorkAges 18–80 - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Carmel, New YorkAges 12 years+ - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Maspeth, New YorkAges 16–80 - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Maspeth, New YorkAges 16–80 - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Utica, New YorkAges 18–80 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
New York, New YorkAges 18–75 - NCT06636656RecruitingPhase 2
Testing a new drug for ulcerative colitis after other treatments failed
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
New York, New YorkAges 18–80 - NCT06619990RecruitingPhase 1/Phase 2
Study of XmAb942 for active ulcerative colitis
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Albany, New YorkAges 18–75 - NCT04314375RecruitingPhase 4
Budesonide tablets for children with mild to moderate ulcerative colitis
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
The Bronx, New YorkAges 5–17 - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
New York, New YorkAges 18–64 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
New York, New YorkAges 2–17 - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
New York, New YorkAges 2–19 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Fresh Meadows, New YorkAges 18 years+ - NCT06095128RecruitingPhase 4
Combination therapy for ulcerative colitis
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
New York, New YorkAges 18–65 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
New York, New YorkAges 18–75 - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
New York, New YorkAges 18–85 - NCT07158242RecruitingPhase 3
Study of a Medication for Children with Active Ulcerative Colitis
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
Lake Success, New YorkAges 2–17 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
New York, New YorkAges 2–17 - NCT06651281RecruitingPhase 3
Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
New York, New YorkAges Any age - NCT06405087RecruitingPhase 3
Long-term study of vedolizumab for children with IBD
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
New York, New YorkAges 2–17 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
New Hyde Park, New YorkAges 2 years+
Ulcerative Colitis trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- New York Gastroenterology Associates · 4 studies
- NYU Langone Health · 4 studies
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- MedTraits NY - Site Number: 8400045 · 2 studies
- New York Gastroenterology Associates - Site Number: 8400009 · 2 studies
- Bausch Health Site 006
- Cohen Children's Medical Center Northwell - BRANY - PPDS - PIN
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ulcerative Colitis trials in other states
Common questions
- Are there ulcerative colitis clinical trials in New York?
- Yes. We're currently tracking 36 recruiting ulcerative colitis studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.